Speaker illustration

Doctor Sukrut Shah

Rahway (United States of America)

A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C

Event: ESC Congress 2016

Topic: Drug therapy

Session: Lipid-lowering agents - New perspectives

Thumbnail